Trial Profile
Phase I/II, Multi-center, Open Label, Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti Tumor Activity of ASP9521 in Patients With Metastatic Castrate-resistant Prostate Cancer.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs ASP 9521 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors Astellas Pharma
- 01 Sep 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 30 May 2012 Additional locations (France) added as reported by ClinicalTrials.gov record.
- 19 May 2012 Planned number of patients changed from 174 to 186 as reported by European Clinical Trials Database.